vs

Side-by-side financial comparison of Genius Sports Ltd (GENI) and STEPAN CO (SCL). Click either name above to swap in a different company.

STEPAN CO is the larger business by last-quarter revenue ($604.5M vs $510.9M, roughly 1.2× Genius Sports Ltd). STEPAN CO runs the higher net margin — 3.3% vs -12.3%, a 15.6% gap on every dollar of revenue. Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 4.2%).

Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.

Stepan Company is an American manufacturer of specialty chemicals headquartered in Northbrook, Illinois. The company was founded in 1932 by Alfred C. Stepan, Jr., and has approximately 2,000 employees. It is currently run by his grandson, F. Quinn Stepan, Jr. The company describes itself as the largest global merchant manufacturer of anionic surfactants, which are used to enhance the foaming and cleaning capabilities of detergents, shampoos, toothpastes, and cosmetics.

GENI vs SCL — Head-to-Head

Bigger by revenue
SCL
SCL
1.2× larger
SCL
$604.5M
$510.9M
GENI
Higher net margin
SCL
SCL
15.6% more per $
SCL
3.3%
-12.3%
GENI
Faster 2-yr revenue CAGR
GENI
GENI
Annualised
GENI
129.2%
4.2%
SCL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
GENI
GENI
SCL
SCL
Revenue
$510.9M
$604.5M
Net Profit
$-63.0M
$19.7M
Gross Margin
25.2%
10.7%
Operating Margin
-11.5%
4.7%
Net Margin
-12.3%
3.3%
Revenue YoY
1.9%
Net Profit YoY
EPS (diluted)
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENI
GENI
SCL
SCL
Q1 26
$604.5M
Q4 25
$510.9M
$553.9M
Q3 25
$335.4M
$590.3M
Q2 25
$215.2M
$594.7M
Q1 25
$119.7M
$593.3M
Q4 24
$413.0M
$525.6M
Q3 24
$285.8M
$546.8M
Q2 24
$184.1M
$556.4M
Net Profit
GENI
GENI
SCL
SCL
Q1 26
$19.7M
Q4 25
$-63.0M
$5.0M
Q3 25
$10.8M
Q2 25
$-47.3M
$11.3M
Q1 25
$-25.5M
$19.7M
Q4 24
$-85.5M
$3.4M
Q3 24
$-47.1M
$23.6M
Q2 24
$-35.5M
$9.5M
Gross Margin
GENI
GENI
SCL
SCL
Q1 26
10.7%
Q4 25
25.2%
9.3%
Q3 25
24.2%
12.0%
Q2 25
19.1%
12.1%
Q1 25
10.7%
12.7%
Q4 24
16.7%
10.8%
Q3 24
20.5%
13.8%
Q2 24
18.6%
12.5%
Operating Margin
GENI
GENI
SCL
SCL
Q1 26
4.7%
Q4 25
-11.5%
1.9%
Q3 25
-15.3%
3.7%
Q2 25
-21.0%
3.0%
Q1 25
-20.3%
4.8%
Q4 24
-18.0%
1.5%
Q3 24
-13.9%
4.4%
Q2 24
-16.8%
3.4%
Net Margin
GENI
GENI
SCL
SCL
Q1 26
3.3%
Q4 25
-12.3%
0.9%
Q3 25
1.8%
Q2 25
-22.0%
1.9%
Q1 25
-21.3%
3.3%
Q4 24
-20.7%
0.6%
Q3 24
-16.5%
4.3%
Q2 24
-19.3%
1.7%
EPS (diluted)
GENI
GENI
SCL
SCL
Q1 26
$0.86
Q4 25
$0.22
Q3 25
$0.47
Q2 25
$0.50
Q1 25
$0.86
Q4 24
$0.14
Q3 24
$1.03
Q2 24
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENI
GENI
SCL
SCL
Cash + ST InvestmentsLiquidity on hand
$280.6M
Total DebtLower is stronger
$328.4M
Stockholders' EquityBook value
$724.5M
$1.2B
Total Assets
$1.1B
$2.3B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENI
GENI
SCL
SCL
Q1 26
Q4 25
$280.6M
$132.7M
Q3 25
$110.2M
$118.5M
Q2 25
$110.2M
$88.9M
Q1 25
$110.2M
$107.5M
Q4 24
$100.3M
$99.7M
Q3 24
$100.3M
$147.3M
Q2 24
$100.3M
$124.7M
Total Debt
GENI
GENI
SCL
SCL
Q1 26
$328.4M
Q4 25
$626.7M
Q3 25
$655.5M
Q2 25
$658.0M
Q1 25
$659.3M
Q4 24
$625.4M
Q3 24
$688.5M
Q2 24
$657.1M
Stockholders' Equity
GENI
GENI
SCL
SCL
Q1 26
$1.2B
Q4 25
$724.5M
$1.2B
Q3 25
$572.4M
$1.2B
Q2 25
$572.4M
$1.2B
Q1 25
$572.4M
$1.2B
Q4 24
$573.0M
$1.2B
Q3 24
$573.0M
$1.2B
Q2 24
$573.0M
$1.2B
Total Assets
GENI
GENI
SCL
SCL
Q1 26
$2.3B
Q4 25
$1.1B
$2.4B
Q3 25
$792.3M
$2.4B
Q2 25
$792.3M
$2.4B
Q1 25
$792.3M
$2.4B
Q4 24
$775.7M
$2.3B
Q3 24
$775.7M
$2.4B
Q2 24
$775.7M
$2.3B
Debt / Equity
GENI
GENI
SCL
SCL
Q1 26
0.28×
Q4 25
0.50×
Q3 25
0.53×
Q2 25
0.53×
Q1 25
0.55×
Q4 24
0.53×
Q3 24
0.56×
Q2 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENI
GENI
SCL
SCL
Operating Cash FlowLast quarter
$81.9M
Free Cash FlowOCF − Capex
$69.6M
FCF MarginFCF / Revenue
13.6%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENI
GENI
SCL
SCL
Q1 26
Q4 25
$81.9M
$60.0M
Q3 25
$-4.8M
$69.8M
Q2 25
$-1.2M
$11.2M
Q1 25
$-14.6M
$6.9M
Q4 24
$14.9M
$68.3M
Q3 24
$-9.2M
$22.7M
Q2 24
$29.5M
Free Cash Flow
GENI
GENI
SCL
SCL
Q1 26
Q4 25
$69.6M
$25.4M
Q3 25
$-14.2M
$40.2M
Q2 25
$-5.8M
$-14.4M
Q1 25
$-16.0M
$-25.8M
Q4 24
$11.3M
$32.1M
Q3 24
$-11.6M
$-4.0M
Q2 24
$-208.0K
FCF Margin
GENI
GENI
SCL
SCL
Q1 26
Q4 25
13.6%
4.6%
Q3 25
-4.2%
6.8%
Q2 25
-2.7%
-2.4%
Q1 25
-13.4%
-4.3%
Q4 24
2.7%
6.1%
Q3 24
-4.1%
-0.7%
Q2 24
-0.0%
Capex Intensity
GENI
GENI
SCL
SCL
Q1 26
Q4 25
2.4%
6.3%
Q3 25
2.8%
5.0%
Q2 25
2.1%
4.3%
Q1 25
1.2%
5.5%
Q4 24
0.9%
6.9%
Q3 24
0.9%
4.9%
Q2 24
5.3%
Cash Conversion
GENI
GENI
SCL
SCL
Q1 26
Q4 25
11.99×
Q3 25
6.44×
Q2 25
0.99×
Q1 25
0.35×
Q4 24
20.38×
Q3 24
0.96×
Q2 24
3.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GENI
GENI

Segment breakdown not available.

SCL
SCL

Surfactants$453.7M75%
Polymers$130.0M22%
Specialty Products$20.8M3%

Related Comparisons